Asset Details
Do you wish to reserve the book?
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Do you wish to request the book?
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cytokine therapy reverses NK cell anergy in MHC-deficient tumors
2014
Overview
Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a mutant form of IL-2 (the \"superkine\" called H9) provided substantial therapeutic benefit for mice specifically bearing MHC class I-deficient tumors, but these treatments were ineffective for mice with matched MHC class I+ tumors. Cytokine efficacy was linked to the reversal of the anergic state of NK cells that specifically occurred in MHC class I-deficient tumors, but not MHC class I+ tumors. NK cell anergy was accompanied by impaired early signal transduction and was locally imparted by the presence of MHC class I-deficient tumor cells, even when such cells were a minor population in a tumor mixture. These results demonstrate that MHC class I-deficient tumor cells can escape from the immune response by functionally inactivating NK cells, and suggest cytokine-based immunotherapy as a potential strategy for MHC class I-deficient tumors. These results suggest that such cytokine therapies would be optimized by stratification of patients. Moreover, our results suggest that such treatments may be highly beneficial in the context of therapies to enhance NK cell functions in cancer patients.
Publisher
American Society for Clinical Investigation
Subject
/ Antigens, Neoplasm - genetics
/ Antineoplastic Agents - pharmacology
/ Histocompatibility Antigens Class I - genetics
/ Histocompatibility Antigens Class I - metabolism
/ Humans
/ Interleukin-12 - pharmacology
/ Interleukin-18 - pharmacology
/ Interleukin-2 - pharmacology
/ Killer Cells, Natural - drug effects
/ Killer Cells, Natural - immunology
/ Lymphoma
/ Major histocompatibility complex
/ Major Histocompatibility Complex - genetics
/ Melanoma
/ Studies
/ Tumors
/ Women
